TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01526590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity Contrast
Description: While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
Study: NCT02230436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early drain removal
Description: Removing drain(s) on postoperative day 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late drain removal
Description: Removing drain(s) on postoperative day 4 or later
Study: NCT01285284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: A previously defined list of songs will be administered by headphones to these patients.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No music
Description: No music will be administered by the headphones connected to the MP3 device.
Study: NCT02192775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MV-NIS
Description: one dose in conjunction with a 4 day course intravenously
Study: NCT01478074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg daily from day -7 until post-nadir ANC \> 1000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m2 daily from day -6 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 daily from day -6 through -2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Natural Killer (NK) cells
Description: Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10\^6 cells/Kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: 0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
Study: NCT01821417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microtextured dental implant treatment
Description: Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant treatment
Description: Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
Study: NCT01535742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Aura-i size 1.5
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 1.5
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Aura-i size 2
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q ILA size 2
Description: Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
Study: NCT02869919

Intervention type: OTHER
Intervention: AKI
Description: Vitamin D levels

Intervention type: OTHER
Intervention: AKI
Description: Vitamin D levels
Study: NCT00544960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101 and docetaxel
Description: AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and docetaxel
Description: placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
Study: NCT04599101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nose Frida nasal suction device
Description: Caregivers will be given a Nose Frida device to remove the child's nasal secretions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulb syringe nasal suction device
Description: Caregivers will be given a bulb syringe device to remove the child's nasal secretions.
Study: NCT00709748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empi Select TENS Device
Description: The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
Study: NCT02790723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sc-rAAV2.5IL-1Ra
Description: Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sc-rAAV2.5IL-1Ra
Description: Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sc-rAAV2.5IL-1Ra
Description: Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
Study: NCT03628963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concerto+
Description: a user-centered, multifunctional and personalized eHealth platform
Study: NCT04103268

Intervention type: OTHER
Intervention: sepsis
Description: patients in the ICU with infection called sepsis
Study: NCT05389891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemoglobinopathy Nursing Program
Description: Hemoglobinopathy Nursing Program is more informative for Groupe 1 than Group 2
Study: NCT03946800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1191
Description: Subjects will receive MEDI1191 (at least twice)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI1191
Description: Subjects will receive MEDI1191 (at least twice)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subject will receive durvalumab every 4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subject will receive durvalumab every 4 weeks
Study: NCT06190691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study: NCT01181505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Study: NCT03264963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone game play
Description: Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Recording of sleep environment 2 nights per week for 12 weeks
Study: NCT02507778

Intervention type: DEVICE
Group type: OTHER
Intervention: CellCollectorTM (Gilupi, Germany) needle
Description: needle will be inserted before and after biopsy and will measure circulating tumor cells.
Study: NCT02377037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic cost and HR associated with distinct postural behaviors
Description: The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic cost and HR associated with distinct postural behaviors
Description: The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic cost and HR associated with distinct postural behaviors
Description: The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
Study: NCT01081041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously
Study: NCT06082414

Intervention type: OTHER
Intervention: no interventions
Description: no interventions because of an observational study

Intervention type: OTHER
Intervention: no interventions
Description: no interventions because of an observational study

Intervention type: OTHER
Intervention: no interventions
Description: no interventions because of an observational study
Study: NCT01737281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive outreach
Description: Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual smoking cessation care from VA clinical staff.
Study: NCT03369821

Intervention type: DIAGNOSTIC_TEST
Intervention: Beta Cell Loss and Immune Function
Description: Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beta Cell Loss and Immune Function
Description: Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beta Cell Loss and Immune Function
Description: Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beta Cell Loss and Immune Function
Description: Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beta Cell Loss and Immune Function
Description: Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.

Intervention type: OTHER
Intervention: Immune Function with RNAseq
Description: Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).

Intervention type: OTHER
Intervention: Immune Function with RNAseq
Description: Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).

Intervention type: OTHER
Intervention: Immune Function with RNAseq
Description: Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).

Intervention type: OTHER
Intervention: Immune Function with RNAseq
Description: Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).

Intervention type: OTHER
Intervention: Immune Function with RNAseq
Description: Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
Study: NCT01960075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosphenytoin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic acid
Study: NCT02820363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERAMENT|G
Description: Surgical repair of tibia fracture, CERAMENT™\|G applied to bony voids.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC treatment
Description: surgical repair of tibial fracture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC treatment
Description: surgical repair of tibial fracture
Study: NCT05851599

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SKF7® Labisia pumila standardized extract
Description: Botanical extract of Labisia pumila (Kacip Fatimah)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKF7® Labisia pumila standardized extract
Description: Botanical extract of Labisia pumila (Kacip Fatimah)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKF7® Labisia pumila standardized extract
Description: Botanical extract of Labisia pumila (Kacip Fatimah)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKF7® Labisia pumila standardized extract
Description: Botanical extract of Labisia pumila (Kacip Fatimah)
Study: NCT02571790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation optimized virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical relaxation (without Virtual Reality)
Study: NCT01618890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic venous pressure gradient measurement
Description: Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement\< 12 mmHg or \>20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up.
Study: NCT03070717

Intervention type: PROCEDURE
Intervention: Observation & Diagnosis
Description: SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
Study: NCT01491074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 280 mg
Description: Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% 100 ml
Description: Placebo
Study: NCT04795310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser
Description: PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.
Study: NCT00671008

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT02465996

Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE examination
Description: All FD patients received pCLE examination.

Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE examination
Description: All FD patients received pCLE examination.

Intervention type: DRUG
Group type: OTHER
Intervention: Puyuanhewei
Description: FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.

Intervention type: DRUG
Group type: OTHER
Intervention: Puyuanhewei
Description: FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
Study: NCT04498195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increased exercise and physical activity
Description: Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
Study: NCT03992534

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LACTIN-V
Description: Vaginal supplementation with L. crispatus CTV-05.
Study: NCT02468102

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban \[od\], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).

Intervention type: DRUG
Intervention: Standard of care drugs
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study: NCT04615182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
Study: NCT04459286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide and atazanavir/ritonavir
Description: 1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
Study: NCT02993939

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Ultrasound guided single shot block above the clavicle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular-suprascapular block
Description: Combined block of nerves far away from phrenic nerve
Study: NCT03548805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ologen® Collagen Matrix
Description: Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with low dose mitomycin C
Description: Trabeculectomy with low dose MMC